home / stock / konef / konef news

KONEF News and Press, KetamineOne Capital Limited From 12/22/22

Stock Information
Company Name: KetamineOne Capital Limited
Stock Symbol: KONEF
Market: OTC
Website: wellbeingdigital.co
Menu
KONEF KONEF Quote KONEF Short KONEF News KONEF Articles KONEF Message Board
Get KONEF Alerts

News, Short Squeeze, Breakout and More Instantly...
KONEF - Wellbeing Subsidiary KGK Science Receives Approval for First-of-its-Kind Psylocibin Clinical Trial

KGK has received approval from Health Canada for Phase II clinical trial to test the efficacy of psilocybin on Fragile X syndrome Wellbeing Digital Sciences Inc. (“ Wellbeing” or the “ Company ”) (NEO: MEDI ) (OTC: KONEF ) (FRA: SQ2 ), a...
KONEF - Wellbeing Subsidiary KGK Science Awarded Cannabis Research License from Health Canada

The Research License greatly reduces the timelines required for conducting cannabis research as it eliminates the need for obtaining a project specific cannabis research license Wellbeing Digital Sciences Inc. (“ Wellbeing” or the “ Company ”) (NEO: ...

KONEF - Wellbeing Subsidiary KGK Science Announces Successful Results of UP446, a Nutraceutical Ingredient, in Positive Immune Defense Response

A randomized, triple-blind, placebo-controlled clinical trial involving supplementation with a bioflavonoid ingredient UP446 provides evidence for a robust, healthy immune response in healthy adults following influenza vaccination. Wellbeing Digital Sciences Inc. (“ Wellbeing&#...

KONEF - Wellbeing Subsidiary KGK Science Submits CTA for Phase IIA Clinical Trial

KGK has submitted a clinical trial application for Phase IIa clinical trial to test the efficacy of psilocybin on Fragile X syndrome Wellbeing Digital Sciences Inc. (“ Wellbeing” or the “ Company ”) (NEO: MEDI ) (OTC: KONEF ) (FRA: SQ2 )...
KONEF - Wellbeing Subsidiary Mindscape Treats its 1,000th Patient

Clinic reaches patient milestone in less than two years since being acquired by Wellbeing Digital Sciences Wellbeing Digital Sciences Inc. (“ Wellbeing” or the “ Company ”) (NEO: MEDI ) (OTC: KONEF ) (FRA: SQ2 ), an evidenc...

KONEF - Wellbeing Digital Announces the Appointment of Mohammad Sharifi to Board of Directors

Wellbeing Digital Sciences Inc. (“ Wellbeing ” or the “ Company ”) (NEO: MEDI ) (OTC: KONEF ) (FRA: SQ2 ), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, includin...

KONEF - Wellbeing Digital Announces Resignation of Directors

Wellbeing Digital Sciences Inc. (“ Wellbeing” or the “ Company ”) (NEO: MEDI ) (OTC: KONEF ) (FRA: SQ2 ), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including...
KONEF - Wellbeing Subsidiary KGK Science Enters into Research Contract With Nova Mentis for Phase II A Clinical Trial

KGK to conduct Phase II clinical trial to test the efficacy of psilocybin on Fragile X syndrome Wellbeing Digital Sciences Inc. (“ Wellbeing” or the “ Company ”) (NEO: MEDI ) (OTC: KONEF ) (FRA: SQ2 ), an evidence-based men...

KONEF - Wellbeing Subsidiary KGK Science Announces Successful Delivery of CBD and THC Through the Skin of Healthy Volunteers

Gefion Canada GT4 technology was used to deliver cannabidiol (CBD) and tetrahydrocannabinol (THC) to healthy volunteers in the form of a topical cream applied to the skin Wellbeing Digital Sciences Inc. (“ Wellbeing” or the “ Company ”) (N...

KONEF - Wellbeing Digital Subsidiary KGK to Participate in Microdose Wonderland Miami Conference

Wellbeing Digital Sciences Inc. (“ Wellbeing” or the “ Company ”) (NEO: MEDI ) (OTC: KONEF ) (FRA: SQ2 ), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including...
Previous 10 Next 10